Ozempic works well for weight loss, though it’s not officially approved for that purpose. In clinical trials, the active ingredient semaglutide produced average weight loss of about 14% to 19% of body weight over roughly 68 to 72 weeks, depending on the dose. That said, results vary significantly from person to person, and roughly 1 in 5 people don’t respond meaningfully to the medication.
What Ozempic Does in Your Body
Ozempic belongs to a class of drugs that mimic a natural gut hormone called GLP-1. This hormone normally spikes after you eat, signaling your body to release insulin and telling your brain you’re full. Semaglutide is a synthetic version that lasts much longer than the natural hormone, keeping those signals active for days rather than minutes.
The weight loss comes from two main effects. First, semaglutide slows how fast your stomach empties, so food sits longer and you feel full sooner during meals. Second, it acts on appetite centers in the brain, reducing hunger and dampening the reward you feel from eating. The combined result is that most people simply eat less without feeling like they’re white-knuckling a diet.
How Much Weight People Actually Lose
The most robust data comes from the STEP clinical trial program. In the STEP UP trial, participants on the higher 7.2 mg dose of semaglutide lost an average of 18.7% of their body weight over 72 weeks, while those on the standard 2.4 mg dose (the same dose used in Wegovy) lost 15.6%. The placebo group lost just 3.9%. For context, someone starting at 220 pounds could expect to lose roughly 34 to 41 pounds on semaglutide over that period.
The timeline matters for setting expectations. Clinical data shows about a 2% body weight reduction in the first four weeks, which is modest. By six months, most people are down 6% to 10%. The losses continue to accumulate through the first year and into the second, though the rate slows as you approach a new stable weight.
Not everyone responds equally. A study tracking real-world patients found that about 22.5% were non-responders, meaning they lost less than 3% of their weight at three months or less than 5% at six months. If you’re not seeing meaningful results by the three-month mark, that’s a signal worth discussing with your prescriber.
Ozempic vs. Wegovy: Same Drug, Different Label
This is a common source of confusion. Ozempic and Wegovy contain the same active ingredient, semaglutide, made by the same company. Ozempic is FDA-approved for type 2 diabetes management and tops out at a 2 mg weekly dose. Wegovy is the version approved specifically for weight management, with doses going up to 2.4 mg. When doctors prescribe Ozempic for weight loss in someone without diabetes, that’s technically off-label use.
The practical difference comes down to insurance coverage and cost. Because Ozempic is approved for diabetes, insurers will typically cover it for that diagnosis. Getting coverage for weight loss alone is harder. Without insurance, the retail price for a one-month supply of Ozempic runs around $1,475.
How It Compares to Tirzepatide
Tirzepatide (sold as Mounjaro for diabetes and Zepbound for weight loss) is the closest competitor, and head-to-head data shows it’s more effective. In the SURMOUNT-5 trial, tirzepatide produced 20.2% body weight loss compared to 13.7% for semaglutide. In absolute terms, that translated to about 50 pounds lost with tirzepatide versus 33 pounds with semaglutide. Tirzepatide works on two gut hormones instead of one, which appears to account for the difference.
That doesn’t make semaglutide a poor choice. A 14% weight loss is clinically significant and enough to improve blood pressure, blood sugar, joint pain, and sleep apnea in many people. Some patients also tolerate one drug better than the other, so effectiveness on paper isn’t the only consideration.
The Dose Escalation Process
Ozempic uses a gradual dosing schedule to minimize side effects. You start at 0.25 mg once a week for four weeks, which is essentially a “getting used to it” phase with little weight loss expected. At week five, the dose increases to 0.5 mg. From there, your prescriber can increase to 1 mg and eventually up to the maximum of 2 mg, with at least four weeks between each step up.
This slow climb matters because the side effects are dose-dependent. Nausea, vomiting, diarrhea, abdominal pain, and constipation are the most common issues, reported in at least 5% of patients. The majority of these gastrointestinal symptoms occur during dose escalation and tend to settle once your body adjusts to each new level. Eating smaller meals, avoiding fatty foods, and staying hydrated can help during these transitions.
What Happens When You Stop
This is the part that catches many people off guard. A systematic review published in The BMJ estimated that people regain weight at a rate of about 0.8 kg (1.8 pounds) per month after stopping newer drugs like semaglutide. Within the first year off the medication, the average regain was roughly 10 kg (22 pounds). The researchers projected a return to baseline weight approximately 1.5 years after stopping treatment.
This pattern makes sense when you consider how semaglutide works. It doesn’t permanently reset your appetite or metabolism. It suppresses hunger while you’re taking it, and when you stop, those hunger signals return. This is why most obesity medicine specialists now treat these medications as long-term, similar to blood pressure drugs, rather than short courses you eventually stop. If you’re considering Ozempic for weight loss, planning for indefinite use is more realistic than expecting to take it for a year and maintain results on your own.
Factors That Affect Your Results
Semaglutide is not a standalone treatment. The clinical trials that produced those impressive numbers also included lifestyle interventions, meaning participants were counseled on diet and physical activity. People who combine the medication with consistent exercise and dietary changes tend to lose more weight and hold onto more of it if they eventually discontinue.
Starting weight, metabolic health, and individual biology all play a role in how much you lose. People with type 2 diabetes generally lose less weight on semaglutide than people without diabetes, likely because of differences in insulin resistance and metabolism. Age, sex, and baseline eating patterns also contribute to the wide range of outcomes. The 18.7% average from clinical trials is just that: an average. Some people lose considerably more, and roughly a quarter lose considerably less.